Literature DB >> 30250609

Recruitment and significance of Th22 cells and Th17 cells in malignant ascites.

Xian-Wen Yang1, Hai-Xing Jiang1, Ronge Lei1, Wei-Shun Lu1, Shi-Hui Tan1, Shan-Yu Qin1.   

Abstract

T helper (Th)22 and Th17 cells are implicated in the pathogenesis of a number of types of cancer. However, the function of Th22 and Th17 cells in malignant ascites (MA) remains unknown. The present study aimed at examining the distribution, phenotypes, recruitment, and prognostic value of Th22 and Th17 cells in MA from patients with hepatocellular carcinoma (HCC). A total of 26 patients with HCC with MA and 15 healthy controls were included in the present study. The proportion of Th22 cells, Th17 cells, C-C motif chemokine receptor (CCR)4, CCR6 and CCR10 were examined using flow cytometry. Interleukin (IL-)22, IL-17, C-C motif chemokine ligand (CCL)20, CCL22 and CCL27 were investigated using ELISA. In addition, the chemoattractant activity of chemokines for Th22 and Th17 cells in vitro were examined via a chemotaxis assay. The results of the present study demonstrated that Th22 cells, Th17 cells, IL-22 and IL-17 were significantly increased in MA compared with the corresponding blood and peripheral blood from healthy controls. Additionally, Th22 cells expressed increased concentrations of CCR6, CCR4 and CCR10, and Th17 cells expressed increased concentrations of CCR4 and CCR6 in MA compared with the corresponding blood. The chemotaxis assay revealed that CCL20/CCR6, CCL22/CCR4 and CCL27/CCR10 were responsible for the recruitment of Th22 cells into MA, whereas CCL22/CCR4 was responsible for the recruitment of Th17 cells. Furthermore, the patients with an increased number of Th17 cells exhibited an increased survival time compared with patients with a limited number of Th17 cells. Th22 and Th17 cells serve an important function in the development of MA, and the accumulation of Th22 and Th17 cells in MA may be due to a local increase in proinflammatory cytokines and chemokines. Increased Th17 cell numbers in MA may indicate the improvement of patient survival.

Entities:  

Keywords:  T helper 17 cells; T helper 22 cells; chemokines; hepatocellular carcinoma; malignant ascites

Year:  2018        PMID: 30250609      PMCID: PMC6144943          DOI: 10.3892/ol.2018.9316

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  Multiparametric analysis of cytokine-driven human Th17 differentiation reveals a differential regulation of IL-17 and IL-22 production.

Authors:  Elisabetta Volpe; Maxime Touzot; Nicolas Servant; Marie-Annick Marloie-Provost; Philippe Hupé; Emmanuel Barillot; Vassili Soumelis
Journal:  Blood       Date:  2009-08-24       Impact factor: 22.113

2.  The frequency of Th17 and Th22 cells in patients with colorectal cancer at pre-operation and post-operation.

Authors:  Limian Ling; Pingwei Zhao; Guoqiang Yan; Mingxiao Chen; Ting Zhang; Lei Wang; Yanfang Jiang
Journal:  Immunol Invest       Date:  2014-07-15       Impact factor: 3.657

Review 3.  The biology and functions of Th22 cells.

Authors:  Lei Jia; Changyou Wu
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 4.  The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review.

Authors:  Simone Punt; Jessica M Langenhoff; H Putter; Gert Jan Fleuren; Arko Gorter; Ekaterina S Jordanova
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

Review 5.  The current and future management of malignant ascites.

Authors:  E M Smith; G C Jayson
Journal:  Clin Oncol (R Coll Radiol)       Date:  2003-04       Impact factor: 4.126

6.  Differentiation and recruitment of IL-22-producing helper T cells stimulated by pleural mesothelial cells in tuberculous pleurisy.

Authors:  Zhi-Jian Ye; Qiong Zhou; Ming-Li Yuan; Rong-Hui Du; Wei-Bing Yang; Xian-Zhi Xiong; Bo Huang; Huan-Zhong Shi
Journal:  Am J Respir Crit Care Med       Date:  2011-12-28       Impact factor: 21.405

7.  Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation.

Authors:  Hania Kebir; Katharina Kreymborg; Igal Ifergan; Aurore Dodelet-Devillers; Romain Cayrol; Monique Bernard; Fabrizio Giuliani; Nathalie Arbour; Burkhard Becher; Alexandre Prat
Journal:  Nat Med       Date:  2007-09-09       Impact factor: 53.440

8.  Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.

Authors:  Weici Zhang; Yongyan Chen; Haiming Wei; Chaogu Zheng; Rui Sun; Jian Zhang; Zhigang Tian
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

9.  Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

Authors:  Ilona Kryczek; Mousumi Banerjee; Pui Cheng; Linhua Vatan; Wojciech Szeliga; Shuang Wei; Emina Huang; Emily Finlayson; Diane Simeone; Theodore H Welling; Alfred Chang; George Coukos; Rebecca Liu; Weiping Zou
Journal:  Blood       Date:  2009-05-21       Impact factor: 22.113

10.  Th22 cells are associated with hepatocellular carcinoma development and progression.

Authors:  Shanyu Qin; Shijia Ma; Xiaoli Huang; Donghong Lu; You Zhou; Haixing Jiang
Journal:  Chin J Cancer Res       Date:  2014-04       Impact factor: 5.087

View more
  3 in total

Review 1.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands.

Authors:  Jan Korbecki; Szymon Grochans; Izabela Gutowska; Katarzyna Barczak; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

Review 2.  Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity.

Authors:  Kazuhiko Matsuo; Osamu Yoshie; Takashi Nakayama
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

Review 3.  T-Cell Immunity in Pancreatic Cancer.

Authors:  Reham Ajina; Louis M Weiner
Journal:  Pancreas       Date:  2020-09       Impact factor: 3.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.